Despite discontinuing the ex vivo program, the company is planning ... mouse model suggested that Editas’ preclinical in vivo editing candidate using the LNP3 (the latest version of their ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

Editas Medicine, Inc. announced significant advancements in its gene editing research, achieving in vivo preclinical proof of concept for editing hematopoietic stem cells (HSCs) in non-human ...

Beam is pursuing a long-term, staged development strategy for sickle cell disease that includes three “waves” of ...